AU Patent

AU2006214437C1 — Aptamer therapeutics useful in the treatment of complement-related disorders

Assigned to Astellas US LLC · Expires 2013-03-28 · 13y expired

What this patent protects

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

USPTO Abstract

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

Patent Metadata

Patent number: AU2006214437C1
Jurisdiction: AU
Classification: —
Expires: 2013-03-28
Drug substance claim: No
Drug product claim: No
Assignee: Astellas US LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.